Yosef Yarden, PhD

Non-small cell lung cancer (NSCLC) is a major type of lung cancer that can affect smokers and nonsmokers. Dr. Yarden focuses on drug-resistant NSCLC carrying mutations in the epidermal growth factor receptor gene (EGFR). EGFR-mutated lung tumors sequentially develop new mutations during treatment with 1st-, 2nd-, and 3rd-generation drugs known as tyrosine kinase inhibitors (TKIs). He and his lab hope to test an experimental upfront treatment regimen that combines the power of antibodies and TKIs to prolong patient survival. 

View Grant Recipient Profile